A detailed history of Profund Advisors LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 103,974 shares of AKBA stock, worth $176,755. This represents 0.01% of its overall portfolio holdings.

Number of Shares
103,974
Previous 55,062 88.83%
Holding current value
$176,755
Previous $200,000 40.0%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

BUY
$2.7 - $4.01 $132,062 - $196,137
48,912 Added 88.83%
103,974 $280,000
Q2 2025

Aug 07, 2025

BUY
$1.55 - $3.97 $15,717 - $40,255
10,140 Added 22.57%
55,062 $200,000
Q1 2025

May 08, 2025

BUY
$1.69 - $2.84 $12,255 - $20,595
7,252 Added 19.25%
44,922 $86,000
Q4 2024

Feb 13, 2025

BUY
$1.26 - $2.13 $47,464 - $80,237
37,670 New
37,670 $70,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.